British Business Bank’s life sciences backing surpasses £1bn
Press release
- £832m in commitments across 20 life sciences funds, with £3.1bn of private sector leverage
- £302m invested in 28 life sciences scale ups half of which are university spinouts
- Total backing hits £1.13 billion
The British Business Bank’s backing for UK life sciences has surpassed £1bn (£1.13bn). This milestone reflects a significant increase in its recent investment activity and cements its critical role in this strategically important sector.
Today the Bank has also announced a €58m commitment to Sofinnova Crossover Fund II, a late-stage growth-oriented fund. This supports the Bank’s strategy to create deeper pools of funding for UK companies and follows its previous commitment to Sofinnova Capital XI, the manager’s flagship strategy.
For more than a decade, the British Business Bank has helped close the UK’s life sciences funding gap by backing specialist funds and investing directly in companies. This support has helped businesses commercialise breakthrough research, scale in the UK and strengthened the life sciences investment market.
Backing specialist fund managers
The Bank regularly makes anchor commitments to specialist funds. The Bank has made commitments of £832m across 20 life sciences funds, which have achieved £3.1bn of private sector leverage bringing in over £3 pounds for every pound invested.
Recent fund commitments include £135m across two new Advent Life Sciences funds, a £100m cornerstone commitment to Apposite Healthcare Growth I, and a $100m commitment to SV Health Investors’ flagship SV8 Biotech Fund LP.
Boosting later stage funding rounds
The Bank began direct investing in 2021 to increase the size of later stage funding rounds and has since become one of the UK's most active later-stage investors in life sciences. The Bank has now invested £302m directly into 28 life sciences scale ups. Recent investments include £25m in Alchemab Therapeutics, the Bank’s largest single direct life sciences investment to date; $20m to support Redx Pharma’s growth near Manchester; and £15m in Cambridge spinout T-Therapeutics.
Compelling returns and commercial success
The UK regularly produces life sciences companies with breakthrough innovation, but the sector is particularly reliant on patient capital to commercialise research, with step changes in value typically occurring when key milestones such as clinical trial results or regulatory approvals are achieved.
Recent exits from the Bank’s portfolio demonstrate the global commercial potential of UK life sciences include Merck & Co. acquired EyeBio in 2024 in a deal worth up to $3bn, while Terumo acquired OrganOx for $1.5bn in 2025. In 2026, Bank-backed university spinout Myricx Bio agreed to be acquired by Novartis for up to $1.5bn.
Leandros Kalisperas, Chief Investment Officer at the British Business Bank said
The Bank is here to back British science. By supporting specialist fund managers and investing directly in high-growth companies, we are helping scientists convert research into commercial success. The true value of this milestone cannot be measured solely in pounds invested, but in the economic growth it creates, and the patients’ lives it improves.
From the discovery of penicillin to pioneering advances in DNA sequencing, British science has helped shape modern medicine and improve millions of lives around the world. Our scientific strength is a major investment opportunity, but realising that potential requires deep pools of capital through years of development.
Professor Chris Molloy, CEO of the BioIndustry Association, said:
The British Business Bank plays a welcome and vital role to turn world-class science into breakthrough medicines, skilled jobs and long-term value for taxpayers. The Bank is accelerating and closing the growth capital gap with deeper pools of late-stage capital to enable our most promising businesses scale and stay in the UK.
Antoine Papiernik, Chairman and Managing Partner, Sofinnova Partners said:
The UK produces world-class science, and its companies need specialist capital at the stages where it is hardest to find, something the British Business Bank has long understood. We are delighted to be building on our partnership with them, and to be backing more of the UK's best companies as they scale.
Further Information
If you are a journalist and have a media enquiry, please contact [email protected].
Notes to editors
About the British Business Bank
The British Business Bank is the UK government’s economic development bank. Established in November 2014, its mission is to drive economic growth by helping smaller businesses get the finance they need to start, scale and stay in the UK. Its remit is to design, deliver and efficiently manage UK-wide smaller business access to finance programmes for the UK government.
In 2025/26Read footnote text 1 , the Bank supported UK smaller businesses to access £9.4bn of finance, made up of £1.3bn of public funding, £4.3bn of private capital crowded in by the Bank and £3.7bn of lending the Bank guaranteed. The funding benefited 38,000 UK businesses, including around 30,000 businesses the Bank had not previously helped to fund.
British Business Bank plc is a public limited company registered in England and Wales, registration number 08616013, registered office at Steel City House, West Street, Sheffield, S1 2GQ. It is a development bank wholly owned by HM Government. British Business Bank plc and its subsidiaries are not banking institutions and do not operate as such. With the exception of BBB Investment Services Limited they are not authorised or regulated by the Prudential Regulation Authority or the Financial Conduct Authority. BBB Investment Services Limited is authorised and regulated by the Financial Conduct Authority. A complete legal structure chart for the group can be found at british-business-bank.co.uk.
-
Return to footnote location
1
Figures as at end March 2026
Latest news
-
Read more about British Business Bank agrees £35m Additional Tier 1 capital facility with Cynergy Bank Press release
16 November 2026 -
Read more about British Business Bank commits €75m to Plural to build frontier technology champions Press release
16 November 2026 -
Read more about British Business Bank commits additional £40m to Harwood Private Capital to support ambitious smaller businesses across the UK Press release
12 November 2026